Genelux Corporation Announces Proposed Public Offering of Common Stock

Company Overview - Genelux Corporation is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for patients with aggressive and/or difficult-to-treat solid tumors [5] - The company's lead product, Olvi-Vec, is currently being evaluated in multiple clinical trials for various cancer types, including ovarian cancer and non-small-cell lung cancer [5] Proposed Offering - Genelux has announced a proposed underwritten public offering of its common stock, with an expectation to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares sold [1] - The offering is subject to market conditions and customary closing conditions, with no assurance on the completion or terms of the offering [1] Management and Regulatory Details - Lucid Capital Markets is acting as the sole book-running manager for the proposed offering [2] - The offering is being made under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) [3]